PT  - JOURNAL ARTICLE
AU  - Finney, Caitlin A.
AU  - Delerue, Fabien
AU  - Gold, Wendy A.
AU  - Brown, David A.
AU  - Shvetcov, Artur
TI  - Artificial intelligence-driven meta-analysis of brain gene expression identifies novel gene candidates and a role for mitochondria in Alzheimer’s Disease
AID  - 10.1101/2022.02.02.22270347
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.02.22270347
4099  - http://medrxiv.org/content/early/2022/10/12/2022.02.02.22270347.short
4100  - http://medrxiv.org/content/early/2022/10/12/2022.02.02.22270347.full
AB  - Alzheimer’s disease (AD) is the most common form of dementia. There is no treatment and AD models have focused on a small subset of genes identified in familial AD. Microarray studies have identified thousands of dysregulated genes in the brains of patients with AD yet identifying the best gene candidates to both model and treat AD remains a challenge. We performed a meta-analysis of microarray data from the frontal cortex (n = 697) and cerebellum (n = 230) of AD patients. A two-stage artificial intelligence approach, with both unsupervised and supervised machine learning, combined with a functional network analysis was used to identify functionally connected and biologically relevant novel gene candidates in AD. We found that in the frontal cortex, genes involved in mitochondrial energy, ATP, and oxidative phosphorylation, were the most significant dysregulated genes. In the cerebellum, dysregulated genes were involved in mitochondrial cellular biosynthesis (mitochondrial ribosomes). There was little overlap between dysregulated genes between the frontal cortex and cerebellum. A further functional network analysis of these genes identified that two downregulated genes, ATP5L and ATP5H, which both encode subunits of ATP synthase (mitochondrial complex V) may play a role in AD. Combined, our results suggest that mitochondrial dysfunction, particularly a deficit in energy homeostasis, may play an important role in AD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a Macquarie University Research Acceleration Scheme Grant (MQRAS 173983854) awarded to C.A.F. and A.S.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used publicly available datasets from the Gene Expression Omnibus (GEO) database. The accession numbers for the datasets are: GSE44770, GSE33000, and GSE44768.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors